Thermo Fisher Scientific Expands its Global Biologics and Steriles Manufacturing Capabilities in China
Search Patheon
Recent searches
Clear History
Suggestions
All Results
Recent searches
Clear History
Suggestions
All Results
Search
US | EN
Strategic CDMO partnerships: Leveraging infrastructure investments and innovation to accelerate biologics development
Whitepaper
Rising to the challenges of biologics development in this period of disruptive change requires an appreciation for the science, technology, and market forces driving the transformation and a willingness to adopt strategies that align with these changes. For most pharmaceutical and biotech companies, this means identifying trusted partners who can provide access to innovative technologies and methodologies, sufficient manufacturing capacity for growing biologics demand, deep expertise in navigating regulatory channels, and the operational efficiencies needed to accelerate speed to market. This report provides a roadmap for assessing and selecting the right partner to get promising biological therapies to patients quickly.